Methofill (Methotrexate)

Methotrexate functions as a folate antagonist by inhibiting the enzyme dihydrofolate reductase. This inhibition blocks the formation of tetrahydrofolate, a co‑factor essential for synthesizing purine nucleotides and thymidylate, thereby reducing DNA, RNA and protein production in rapidly dividing cells such as immune cells and cancer cells.

The specific dose of Methofill is determined by the treating physician based on the patient’s diagnosis, disease severity, renal and hepatic function, and response to therapy. Dosing regimens vary widely across indications, and the prescriber tailors the amount and frequency to each individual case.

Methofill is classified as contraindicated in pregnancy because methotrexate is known to be teratogenic and can cause fetal malformations or loss. It is also generally avoided during breastfeeding, as the drug can be excreted in breast milk and may harm the infant. Alternative therapies should be considered for pregnant or nursing patients.

To request Methofill, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methofill (methotrexate) is an antimetabolite immunosuppressant, often used as a first‑line disease‑modifying agent for rheumatoid arthritis and psoriasis. Compared with biologic agents such as TNF‑alpha inhibitors, methotrexate is less expensive and administered via injection or oral routes, but may have a slower onset of action and a distinct safety profile that requires regular monitoring.

Methofill should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product is temporarily removed from refrigeration, it should be returned to the recommended temperature range within a short period to maintain stability.

Methofill is supplied as a sterile solution for intravenous or subcutaneous injection. Administration is performed by a qualified healthcare professional in a clinical setting. The injection site and technique follow standard aseptic procedures, and the volume is typically diluted in an appropriate carrier fluid when given intravenously.

The most serious risks include myelosuppression leading to severe neutropenia or anemia, pulmonary toxicity such as interstitial pneumonitis, and significant hepatic injury reflected by marked elevation of liver enzymes. Rare but life‑threatening reactions can involve severe skin disorders like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and renal failure in susceptible individuals.

Methofill is contraindicated in patients who are pregnant, nursing, or have known hypersensitivity to methotrexate. It should also be avoided in individuals with severe renal or hepatic impairment, uncontrolled infections, or pre‑existing pulmonary disease that could be exacerbated by the drug. A thorough medical assessment is required before initiating therapy.